Activated cytotoxic T lymphocytes and natural killer cells, which are involved in the pathogenesis of GVHD and viral infections after SCT produce granzymes (Grs). This study performed an ELISA in the serum of 86 patients at various time points before and after Allo-SCT to investigate GrA and GrB levels as potential markers for these serious complications. The increase in Gr levels from the day of transplantation until the appearance of the complication was highly predictive. If GrA increased to three times its pretransplant level, the cumulative incidence of developing acute GVHD was 73% and for CMV infection 68%, in comparison with 45 and 35%, respectively, for patients without these complications. A strong increase in GrA level correlated with clinical severity of acute GVHD. No correlation was observed with early relapse or long-term overall survival. In addition to clinical parameters, a strong increase in GrA levels was identified as an independent marker for the occurrence of acute GVHD as well as for CMV infection. Similar effects were observed with GrB. In conclusion, Gr protein levels can also be used as a marker for complications after Allo-SCT.
Introduction
GVHD and viral complications, such as CMV reactivation, still represent the main causes of morbidity and mortality after Allo-SCT, so that the search for predictive markers for these complications is still justified. GVHD caused by host-reactive antigenic differences and viral infections is mediated by activated cytotoxic T lymphocytes and natural killer cells. The effectiveness of these cells is attributed to the destruction of target cells by at least three mechanisms:
(I) Fas/Fas ligand interaction, (II) TNFa release and (III) granzyme (Gr)/perforin are released singly or jointly. 1 Murine studies have shown that perforin is crucial for the development of severe acute GVHD [2] [3] [4] and that CD8-positive, GrB-positive effector cells mediate MHC class I-dependent acute GVHD. 5, 6 Perforin-and GrB-positive lymphocytes were detected in human lesions of acute GVHD, 7, 8 and increased gene expression of perforin and GrB was detected in patients with acute GVHD, although the transcript levels did not correlate with clinical severity. 9, 10 Knowledge of Gr protein levels during complications after SCT is, however, limited. 9 We measured earlier GrA and GrB production levels in supernatants of pre-transplant mixed lymphocyte cultures from 20 HLAidentical sibling patient/donor pairs using an ELISA, and detected a significant association between enhanced in vitro GrA production levels and acute GVHD grades II-IV. 11 The aim of this study was to evaluate a possible correlation between in vivo GrA and GrB levels and the occurrence of complications during the first 3 months after SCT. GrA and GrB levels were determined by ELISA in the sera of 86 patients at various time points before and after SCT.
Materials and methods

Patients
A total of 86 patients were included in the analysis. The study was approved by the local ethics committee, and all patients gave written informed consent. Detailed patient characteristics are listed in Table 1 . The majority of patients (n ¼ 48) had acute leukemia, and 11 patients had Ph þ CML. Twelve patients were diagnosed with myelodysplastic syndrome, and 15 patients had other diagnoses (multiple myeloma, n ¼ 4; malignant lymphoma, n ¼ 9; osteomyelofibrosis, n ¼ 1; hypereosinophilic syndrome, n ¼ 1). Forty-nine patients were grafted from HLAidentical sibling donors, and 37 patients were transplanted from a 12/12 HLA-antigen-matched volunteer-unrelated donor. Initial GVHD prophylaxis consisted of CYA plus MTX (n ¼ 48) for myeloablative transplants and of CYA plus mycophenolate mofetil or MTX (n ¼ 31) for dose-reduced transplants. Patients with unrelated transplants in remission additionally received low-dose antithymocyte globulin (Thymoglobulin) 5 mg/kg as described. 12 Standard-risk disease was defined as CML in first chronic phase and acute leukemia in first complete remission. All other indications were classified as high-risk disease.
Patients producing high and low GrA or GrB levels (for definition, see below) did not significantly differ with regard to recipient age, donor age, diagnosis, donor type, stem cell source, risk or CMV positivity of the patient. In the cohort with high Gr production, twice as many patients received a dose-reduced conditioning regimen and three times fewer patients received an HLA-mismatched allograft in comparison with the patient group displaying a low Gr increase.
Sera were taken from patients at various time points before and after SCT. After clotting for 30 min, samples were centrifuged at 1575 g and 4 1C and stored at À70 1C until use.
Measurement of Gr levels
GrA and GrB levels were determined with commercially available ELISA (PeliKine Compact human GrA or GrB-ELISA; Sanquin CLB, Amsterdam, The Netherlands). The lowest detectable levels were 1.6 U/ml for GrA and 1.3 U/ml for GrB.
Statistical analysis
All statistical analyses were performed with the NCSS statistical software package (Kaysville, UT, USA). The Gr levels were expressed as median ±s.d. The Wilcoxon signedrank test was used to analyze statistical significance. The cutoff value for the division into high and low Gr production was defined by descriptive analysis and receiver operating characteristic curves with the aim of reaching a specificity of 480%. Coherence with clinical parameters (acute GVHD, CMV infection or relapse before day þ 100) is shown as cumulative incidence with 95% lower and upper confidence interval (CI), whereby death before day þ 100 from any cause other than the complication of interest was considered as competing risk. Overall survival was calculated from the date of transplantation to the date of death from any cause or the date of last follow-up (June 2008). The probability of overall survival was estimated using the Kaplan-Meier method and compared using the log-rank test. 13 Disease relapse/progression was defined as the date of documented relapse or disease progression. All patients with CML had either cytogenetic and/or hematological relapse (documented by conventional metaphase or bcr-abl interphase FISH analysis). CMV infection was defined as the date of documented CMV reactivation or CMV disease. To obtain enough patients for analysis, both cohorts were combined. A logistic regression analysis was used to determine the risk factors for the occurrence of acute GVHD or CMV infection including the following variables: Gr increase (high/low), donor type, risk, source of graft, HLA mismatch, age of recipient and donor, CMV status of recipient and donor, GVHD and CMV infection following SCT.
Results
GrA and GrB levels were determined by ELISA in sera of 86 patients at various time points ranging from day À6 before to day þ 90 after SCT. Low GrA and GrB levels were detected before SCT. Thereafter, GrA levels continuously rose from 24 ± 28 U/ml on day 0 to 60 ± 55 U/ml on days þ 18/ þ 21, and decreased to almost pre-transplant levels at day þ 90 (31±40 U/ml). A similar pattern was observed for GrB, although GrB levels exceeded GrA levels (on day 0 76 ± 130 U/ml with a peak on days þ 18/ þ 21 (138±130 U/ml)).
Until day þ 100, 83 patients were evaluable for complications after SCT. Median GrA and GrB serum levels measured on the day of GVHD diagnosis did not differ from the level seen on days þ 30/ þ 36 in patients not developing GVHD (55 ± 74 vs 45 ± 40 U/ml for GrA and 119±183 vs 118±129 U/ml for GrB, respectively). The rise in GrA and GrB levels from day 0 until GVHD diagnosis, however, was significantly greater in patients with acute GVHD compared with patients without acute GVHD (Table 2) .
Median GrA and GrB serum levels were also not predictive for CMV infection in our SCT cohort. Median GrA levels at the day of diagnosis of CMV infection (55 ± 89 U/ml) were only marginally higher than median GrA levels measured on day þ 40 in patients without this complication (43±42 U/ml). Moreover, GrB levels in patients with CMV infection (112±101 U/ml) did not significantly differ from GrB serum levels measured on day þ 40 in patients without this complication (104±114 U/ ml). Again, the difference in the rise in GrA and GrB levels from the day of transplantation until the day of diagnosis of CMV infection was statistically significant between patients with and without this complication ( Table 2) . As shown in Table 2 , a median increase of 2.4 in GrA and of 1.4 in GrB levels was determined for patients with acute GVHD. Therefore, the patient cohort was further divided into a group displaying a GrA increase of 43 (n ¼ 26) and a GrB increase of 42 (n ¼ 22) and a group with smaller Gr increases with the aim of reaching a specificity of 480%. The cumulative incidence of developing acute GVHD was significantly greater (P ¼ 0.0052) in patients with a strong increase in GrA level compared to patients with an increase of less than 3 (73% (58-92%, 95% CI) vs 45% (33-69%, 95% CI), respectively, Figure 1a) . A strong increase in GrA levels correlated with the severity of acute GVHD. As shown in Table 3 , no GVHD or GVHD grade I was associated with a weaker increase in GrA levels as compared to higher GVHD grades, which were associated with a strong increase in GrA levels.
Furthermore, the cumulative incidence of developing acute GVHD was significantly greater in patients with a strong increase in GrB level compared with patients with an Table 2 Median increase in granzyme levels in patients with or without acute GVHD or CMV infection b Levels on days +30 until +36. This time period was chosen since the median day of occurrence of acute GVHD varied between day +30 and day +36. c Levels on day +40. This time period was chosen since the median day of occurrence of CMV infection was day +40. The median increase from granzyme levels on day 0 until the diagnosis of acute GVHD or CMV infection is shown; ranges are shown in parentheses.
Increase in GrA levels Increase in GrB levels
Cumulative incidence
Cumulative incidence Acute GvHD
Increase in GrA levels > 3
Increase in GrA levels < 3
Increase in GrA levels < 3 Abbreviations: CI ¼ confidence interval; GrA ¼ granzyme A. The cumulative incidence of developing acute GVHD dependent of GrA level increase is shown; the 95% CI for the cumulative incidence is shown in parentheses. 
The risk of developing acute GVHD determined by logistic regression is shown; the 95% CI for the odds ratio is shown in parentheses.
increase of less than 2 (77% (62-97%, 95% CI) vs 46% (35-60%, 95% CI), respectively; P ¼ 0.0193; data not shown). A strong increase in GrB levels correlated with acute GVHD grades 4II and an increase of o2 was associated with GVHD grade I or no GVHD. Enhanced GrA and GrB levels were not expressed in lower overall survival. Cumulative survival for patients with a strong GrA increase was 85% (71-98%, 95% CI), and 95% (89-100%, 95% CI) for patients with a less strong GrA increase (data not shown). Relapse incidence within 100 days after transplantation was also not influenced by elevated GrA levels (9% for both groups; data not shown). Similar results were obtained for GrB (data not shown).
Logistic regression identified enhanced GrA and GrB levels-in addition to clinical parameters-as a significant marker for the occurrence of acute GVHD (Table 4) .
To define patients developing CMV infection, the patient cohort was divided again into a group producing an increase of 43 in GrA levels (n ¼ 22) and of 42 in GrB levels (n ¼ 19). As shown in Figure 1b , the cumulative incidence for developing CMV infection was 68% (51-91%, 95% CI) for patients with a strong increase in GrA levels and 35% (25-50%, 95% CI) for patients with a weak or no increase in GrA levels (P ¼ 0.0079). Overall survival and relapse incidence were similar in both groups (data not shown). The cumulative incidence for the development of CMV infection was greater in the patient cohort with a strong increase in GrB levels (58%; 39-85%, 95% CI vs 41%; 30-55%, 95% CI), but did not reach the level of significance (data not shown). Again, overall survival and relapse incidence did not differ between the two groups (data not shown).
The recipient CMV status was significantly associated solely with the development CMV infection in the logistic regression model (odds ratio of 7.44088 (1.85-29.98, 95% CI), P ¼ 0.00476; data not shown). The correlation with GrA increase did not reach the level of significance (Po0.09).
Discussion
This study aimed to identify patients at risk for developing acute GVHD or CMV infection by measuring GrA and GrB serum levels in SCT patients. The increase in GrA and GrB levels from the day of transplantation until the occurrence was highly predictive. The increase in Gr levels also correlated with severity of acute GVHD.
The amount of Gr in the serum already before transplantation varied between patients and may reflect the constitutive release of proteases by activated lymphocytes. Low Gr levels have also been observed in plasma of healthy individuals.
14 As soon as the lymphocytes are highly activated, as occurs during GVHD, they produce larger amounts of Gr, and a high increase is specific for the development of this complication following SCT. Similar effects have also been observed in solid organ transplantation. Gr (and also perforin) levels were elevated during acute early cardiac rejection, 15, 16 acute pancreas rejection, 17 kidney allograft rejection, [18] [19] [20] acute liver rejection, 21 acute lung rejection 22, 23 and ongoing islet allograft loss. 24 Recent data suggest that molecular monitoring of GrB/perforin gene expression might be used along with clinical criteria to detect presymptomatic acute rejection after intestinal transplantation. 25 In addition, elevated Gr levels were also significantly associated with CMV infection in the uni-and even multivariate analysis in our patient cohort. Similar effects have also been observed after renal and liver transplantation, 21, [26] [27] [28] suggesting that none of these parameters is specific for either complication, GVHD or CMV infection.
Most of the studies published to date analyzed Gr gene expression. Only Jaksch et al. 9 measured GrB protein levels, although in a small cohort of SCT patients, whereby the protein levels correlated well with GrB mRNA levels. This is the first study to analyze Gr levels in the sera of a larger number of SCT patients. The advantage of measuring Gr protein levels is that no further extractions have to be performed.
No data are available on the correlation between Gr levels and relapse after SCT. Studies with perforin-deficient mice indicate that perforin may be crucial for mediating GVL effects. 4, [29] [30] [31] We did not detect a lower relapse rate in patients with increased Gr levels. The relapse rate within 100 days in our cohort was, however, very low and may therefore not be indicative.
In conclusion, measurement of GrA levels in sera of SCT patients might be a simple and useful tool for diagnosing and/or monitoring GVHD and CMV infection following Allo-SCT. However, additional circulating immune markers will be needed to distinguish between alloantigen-and virus-driven immune stimulation following Allo-SCT.
